Together Pharma Ltd (TGPHF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Together Pharma Ltd (TGPHF) trades at $0.09. Together Pharma Ltd. cultivates, produces, stores, and distributes medical cannabis products in Israel. The company's stock trades on the OTC market. Market cap: $18.5M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for TGPHF: TGPHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TGPHF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TGPHF: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Together Pharma Ltd (TGPHF) Healthcare & Pipeline Overview
Together Pharma Ltd. focuses on the medical cannabis sector in Israel, engaging in cultivation, production, storage, and distribution. With a market capitalization of $18.5M and negative profitability, the company navigates a competitive landscape while serving the growing demand for medical cannabis products.
What Is the Investment Thesis for TGPHF?
Together Pharma Ltd. presents a speculative investment opportunity in the emerging medical cannabis market in Israel. With a market capitalization of $18.5M, the company's valuation reflects the high-risk, high-reward nature of the sector. Key value drivers include the expansion of its cultivation and production capacity, successful product launches, and favorable regulatory changes in Israel. The company's negative P/E ratio of -6.54 and a negative profit margin of -6.0% indicate financial challenges. Growth catalysts include increasing acceptance of medical cannabis and expansion into new markets. Potential risks include regulatory hurdles, competition from established players like ATHJF (Aleafia Health Inc.) and BFFTF (BevCanna Enterprises Inc.), and the need for additional capital to fund expansion. Investors should carefully consider these factors before investing.
Based on FMP financials and quantitative analysis
TGPHF Key Highlights
Market capitalization of $18.5M, reflecting its small size within the pharmaceutical industry.
- Negative P/E ratio of -6.54, indicating the company is currently not profitable.
- Gross margin of 15.7%, showing some ability to generate profit from its products.
- Beta of 0.47, suggesting the stock is less volatile than the overall market.
- The company operates in the rapidly growing medical cannabis market in Israel.
Who Are TGPHF's Competitors?
TGPHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATHJF Antisense Therapeutics Limited | $0.01 | -76.00% | $19.6M | 57 |
| BFFTF Biofrontera AG | $0.33 | -95.24% | $19.4M | 46 |
| DIZTF Dignitana AB (publ) | $0.22 | +0.00% | $18.0M | 49 |
| GRAMF TPCO Holding Corp. | $0.16 | -15.36% | $20.1M | 42 |
| HMPSF The Hempshire Group, Inc. | $0.19 | +0.00% | $15.7M | 41 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| ETST Earth Science Tech, Inc. | $0.11 | +29.41% | $31.7M | 61 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TGPHF's Key Strengths?
Established operations in Israel.
- Vertically integrated supply chain.
- Compliance with local regulations.
- Focus on medical cannabis products.
What Are TGPHF's Weaknesses?
Limited geographic diversification.
- Negative profitability.
- Small market capitalization.
- Dependence on the Israeli market.
What Could Drive TGPHF Stock Higher?
Increasing acceptance of medical cannabis in Israel, driving demand for Together Pharma's products.
- Potential regulatory changes in Israel that could expand the medical cannabis market.
- Launch of new cannabis-based products by Together Pharma, catering to different patient needs.
What Are the Key Risks for TGPHF?
Financial-distress signal — its Altman Z-Score of -0.29 sits in the distress zone (elevated bankruptcy risk).
- Regulatory hurdles and licensing requirements in the medical cannabis industry.
- Competition from established players in the cannabis market.
- Need for additional capital to fund expansion and operations.
- Fluctuations in cannabis prices, impacting revenue and profitability.
What Are the Growth Opportunities for TGPHF?
- Expansion of Cultivation Capacity: Together Pharma can increase its cultivation capacity to meet growing demand in the Israeli market. Investing in advanced cultivation technologies and expanding its facilities could significantly boost production volume. The Israeli medical cannabis market is projected to grow, creating a substantial opportunity for Together Pharma to capture a larger market share. This expansion would require capital investment and regulatory approvals, but could lead to increased revenue and profitability.
- Product Diversification: Together Pharma can diversify its product offerings beyond raw cannabis flowers to include oils, edibles, and other value-added products. This diversification can cater to a broader range of patient preferences and increase revenue streams. The market for cannabis-infused products is growing rapidly, offering a significant opportunity for Together Pharma to innovate and capture new market segments. Successful product diversification requires research and development, regulatory compliance, and effective marketing strategies.
- Strategic Partnerships: Forming strategic partnerships with other companies in the cannabis industry, such as distributors, retailers, and research institutions, can enhance Together Pharma's market reach and capabilities. Collaborations can provide access to new markets, technologies, and expertise. Strategic alliances can accelerate growth and reduce risks. Identifying and securing suitable partners is crucial for leveraging this growth opportunity.
- Export Opportunities: As regulations evolve, Together Pharma can explore export opportunities to other countries with legal medical cannabis markets. Exporting products can significantly expand the company's revenue base and reduce its reliance on the Israeli market. Navigating international regulations and establishing distribution networks are essential for successful export operations. The global medical cannabis market is expanding, presenting a long-term growth opportunity for Together Pharma.
- Research and Development: Investing in research and development to develop new cannabis-based therapies and products can provide a competitive advantage. Conducting clinical trials and obtaining patents for innovative products can create significant value. Focusing on specific therapeutic areas, such as pain management or anxiety, can differentiate Together Pharma from its competitors. Successful R&D requires scientific expertise, regulatory approvals, and capital investment.
What Are TGPHF's Competitive Advantages?
- Established presence in the Israeli medical cannabis market.
- Vertically integrated operations, providing control over the supply chain.
- Compliance with Israeli regulations, ensuring product quality and safety.
What Does TGPHF Do?
Together Pharma Ltd., based in Ashkelon, Israel, operates in the medical cannabis industry. The company focuses on the cultivation, production, storage, and distribution of medical cannabis products within Israel. Since its founding, Together Pharma has aimed to establish itself as a key player in the Israeli medical cannabis market, catering to the increasing demand for regulated and quality-controlled cannabis products. The company's operations encompass the entire value chain, from cultivation to distribution, ensuring control over product quality and supply. Together Pharma's strategic focus on the Israeli market allows it to tailor its products and services to local regulations and patient needs. The company's products are intended for medical use, adhering to strict quality standards and regulatory requirements. As the medical cannabis market evolves, Together Pharma continues to adapt its strategies to maintain a competitive edge and expand its market presence. With 145 employees, the company is structured to manage its cultivation, production, and distribution processes efficiently. The company's focus remains on delivering high-quality medical cannabis products to patients in Israel.
What Products and Services Does TGPHF Offer?
- Cultivates medical cannabis plants in Israel.
- Produces medical cannabis products, including flowers, oils, and extracts.
- Stores medical cannabis products in secure facilities.
- Distributes medical cannabis products to pharmacies and patients.
- Complies with Israeli regulations for medical cannabis production and distribution.
- Focuses on the Israeli medical cannabis market.
How Does TGPHF Make Money?
- Generates revenue from the sale of medical cannabis products.
- Operates a vertically integrated business model, controlling cultivation, production, and distribution.
- Focuses on serving the Israeli medical cannabis market.
What Industry Does TGPHF Operate In?
Together Pharma Ltd. operates within the rapidly evolving medical cannabis industry in Israel. The market is characterized by increasing acceptance of medical cannabis for various therapeutic applications. The industry is also subject to evolving regulations and licensing requirements. Competitors include companies such as ATHJF (Aleafia Health Inc.), BFFTF (BevCanna Enterprises Inc.), DIZTF (Dixie Brands Inc.), GRAMF (The Gram Co Inc.), and HMPSF (Hempfusion Wellness Inc.). These companies compete for market share through product innovation, distribution agreements, and strategic partnerships. The growth of the medical cannabis market is driven by increasing awareness of its potential benefits and changing regulatory landscapes.
Who Are TGPHF's Key Customers?
- Patients in Israel with prescriptions for medical cannabis.
- Pharmacies in Israel that dispense medical cannabis products.
- Medical professionals who prescribe medical cannabis to patients.
Financial Health
Together Pharma Ltd's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.29 places it in the distress zone, a signal of elevated financial risk.
TGPHF Valuation & Market Position
With a $18.5M market cap, Together Pharma Ltd sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for Together Pharma Ltd stands at 4.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.2%, showing how much profit it generates from its asset base. TGPHF trades at a trailing price-to-earnings ratio of 21.72, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 13.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.32 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.6%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Together Pharma Ltd operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Ashkelon, IL. The company is led by CEO Nissim Bracha. TGPHF has traded publicly since 2022.
TGPHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Established operations in Israel.
- Vertically integrated supply chain.
- Compliance with local regulations.
- Focus on medical cannabis products.
Bear Case
- Limited geographic diversification.
- Negative profitability.
- Small market capitalization.
- Dependence on the Israeli market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
TGPHF Latest News
No recent news available for TGPHF.
TGPHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TGPHF.
Price Targets
Wall Street price target analysis for TGPHF.
TGPHF MoonshotScore
What does this score mean?
The MoonshotScore rates TGPHF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Nissim Bracha
CEO
Nissim Bracha serves as the CEO of Together Pharma Ltd., overseeing the company's operations in the medical cannabis sector. His leadership is pivotal in guiding the company's strategic direction and ensuring compliance with regulatory standards. With experience in managing teams and resources, Nissim Bracha is responsible for driving the company's growth and expansion in the Israeli market. His background includes experience in business management and strategic planning, which are essential for navigating the complexities of the cannabis industry.
Track Record: Under Nissim Bracha's leadership, Together Pharma has focused on expanding its cultivation and production capabilities to meet the growing demand for medical cannabis in Israel. He has overseen the implementation of quality control measures and the development of strategic partnerships to enhance the company's market position. His focus remains on driving sustainable growth and delivering value to shareholders.
TGPHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Together Pharma Ltd. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and transparency compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in TGPHF.
- OTC Tier: OTC Other
- Limited financial disclosure due to its OTC Other tier listing.
- Lower liquidity, leading to potential price volatility.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Potential for delisting or trading suspensions.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Check for any history of fraud or misconduct.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- The company has been operating for several years.
- The company has a physical presence in Israel.
- The company is involved in the regulated medical cannabis industry.
- The company has a management team in place.
- The company has a website and publishes information about its business.
Together Pharma Ltd Healthcare Stock: Key Questions Answered
What does Together Pharma Ltd do?
Together Pharma Ltd. is involved in the cultivation, production, storage, and distribution of medical cannabis products in Israel. The company operates a vertically integrated business model, overseeing the entire value chain from cultivation to distribution. Together Pharma focuses on serving the Israeli medical cannabis market, providing products to patients with prescriptions through pharmacies and medical professionals.
What do analysts say about TGPHF stock?
As of 2026-03-17, there is no available analyst coverage for Together Pharma Ltd. (TGPHF). The company's small market capitalization and OTC listing may limit analyst interest. Investors should conduct their own thorough research and due diligence before investing in TGPHF. Key valuation metrics include market capitalization, P/E ratio, and gross margin.
What are the main risks for TGPHF?
The main risks for Together Pharma Ltd. include regulatory hurdles, competition from established players, and the need for additional capital. The medical cannabis industry is subject to evolving regulations and licensing requirements, which can impact the company's operations. Competition from larger and more established companies can also pose a challenge.
What are the key factors to evaluate for TGPHF?
Evaluate TGPHF on fundamentals, analyst consensus, and risk factors. Together Pharma Ltd. presents a speculative investment opportunity in the emerging medical cannabis market in Israel. Not financial advice.
How frequently does TGPHF data refresh on this page?
TGPHF's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TGPHF's recent stock price performance?
Together Pharma Ltd (TGPHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established operations in Israel. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TGPHF overvalued or undervalued right now?
Together Pharma Ltd (TGPHF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TGPHF before investing?
Before investing in Together Pharma Ltd (TGPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or delayed.